2. Search Result
Search Result
Results for "

orally ethanol

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-77490A
    1,3-Butanediol
    1 Publications Verification

    		 Environmental Pollutants Endogenous Metabolite Cardiovascular Disease Neurological Disease
    1,3-Butanediol, an orally active ethanol dimer providing a source of calories for human nutrition. 1,3-Butanediol administeration can stimulate the biosynthesis of the ketone body, β-hydroxybutyrate (βHB). 1,3-Butanediol has cerebral protective and hypoglycaemic effect .
    1,3-Butanediol
  • HY-N7103
    Ethyl oleate

    		Environmental Pollutants Endogenous Metabolite Others
    Ethyl oleate is an orally active fatty acid ester formed from the condensation of oleic acid and ethanol. Ethyl oleate is the main fatty acid ethyl ester in the blood after alcohol ingestion. Ethyl oleate has no obvious toxicity to rats and its absorption, distribution and excretionare similar to triacylglycerol. Ethyl oleate can accelerate the drying process of certain foods and can also be used as a liquid lipid component in nanostructured lipid carriers .
    Ethyl oleate
  • HY-114452
    LY2940094
    1 Publications Verification

    BTRX-246040

    		 Opioid Receptor Neurological Disease
    LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .
    LY2940094
  • HY-124410
    Mitoquinol
    3 Publications Verification

    		 Reactive Oxygen Species (ROS) HIF/HIF Prolyl-Hydroxylase Metabolic Disease Inflammation/Immunology
    Mitoquinol is an orally active mitochondria-targeted antioxidant. Mitoquinol can regulate mitochondrial respiration and oxidation. Mitoquinol inhibits ROS production, and improves phagocytosis and glycolysis in ethanol-exposed macrophages via the HIF-1α-PFKP axis. Additionally, Mitoquinol can partially alleviate heat stress-induced decreases in growth performance, inflammatory responses, and metabolic disorders in pigs .
    Mitoquinol
  • HY-N0554
    Escin IA
    1 Publications Verification

    		 HIV Protease Monoamine Oxidase Infection Inflammation/Immunology Cancer
    Escin IA is an oral LOXL2 inhibitor and EMT inhibitor, with selectivity for LOXL2-expressing cells. Escin IA suppresses invasion, migration, and metastasis of breast cancer cells, and acts as the primary anti-TNBC metastasis constituent of Aesculus chinensis Bunge fruit saponin fraction. Escin IA can be used for the research of triple-negative breast cancer, acute inflammation, and ethanol-induced gastric mucosal lesions .
    Escin IA
  • HY-123856
    MY10

    		Phosphatase NF-κB c-Met/HGFR Anaplastic lymphoma kinase (ALK) Cardiovascular Disease Neurological Disease
    MY10 is a potent and orally active receptor protein tyrosine phosphatase (RPTPβ/ζ) inhibitor. MY10 reduces NF-κB p65 expression. MY10 activates tyrosine phosphorylation of c-Met. MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression. MY10 attenuates binge-like ethanol consumption and ethanol reward. MY10 can be used in the study of neurological and vascular diseases .
    MY10
  • HY-B0327
    Irsogladine
    3 Publications Verification

    Dicloguamine

    		 Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related Inflammation/Immunology Cancer
    Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
    Irsogladine
  • HY-W007087
    Valerate sodium

    		GABA Receptor Metabolic Disease
    Valerate sodium is the sodium salt of valeric acid, a short-chain fatty acid, and exhibits oral activity. Valerate sodium reduces binge ethanol intake and decreases blood ethanol concentration in mice, while also exerting anxiolytic effects. Valerate sodium increases GABA levels, regulates epigenetics and alters gut microbiome function. Valerate sodium can be used in research related to excessive alcohol consumption .
    Valerate sodium
  • HY-171844
    CX1739

    		iGluR Neurological Disease Inflammation/Immunology
    CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .
    CX1739
  • HY-114452A
    LY2940094 tartrate
    1 Publications Verification

    BTRX-246040 tartrate

    		 Opioid Receptor Neurological Disease
    LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models .
    LY2940094 tartrate
  • HY-124619
    GPI-1046

    		EAAT HIV Neurological Disease
    GPI-1046 is an orally active, antibiotic-free immunophilin ligand that reduces ethanol intake by upregulating glutamate transporter 1 (GLT1) in the prefrontal cortex (PFC) and nucleus accumbens core (NAc-core). GPI-1046 improves human immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN) by attenuating store-operated calcium (SOC) entry. GPI-1046 has neuroprotective activity .
    GPI-1046
  • HY-122373
    Coprine

    		Aldehyde Dehydrogenase (ALDH) Drug Derivative Metabolic Disease
    Coprine is an orally active disulfiram (HY-B0240)-like component and an inhibitor of aldehyde dehydrogenase. Coprine is isolated from Coprinus atranentarius. Coprine inhibits low Km aldehyde dehydrogenase in rat liver and increases blood acetaldehyde levels during in vivo ethanol metabolism. Coprine does not inhibit semi-purified low Km aldehyde dehydrogenase from rat liver in vitro. Coprine can be used in studies related to alcoholism .
    Coprine
  • HY-12783A
    SCH 50911

    		GABA Receptor Neurological Disease
    SCH 50911 is a selective, orally active, blood-brain barrier permeable GABA-B receptor (GABA-B Receptor) antagonist with an IC50 of 1.1 μM in rats. SCH 50911 blocks baclofen-induced antitussive effects, regulates neuronal firing and GABA release. SCH 50911 promotes spontaneous seizures during withdrawal in ethanol-dependent rats, alters reward-related neurotransmission, and reduces or suppresses lever responding and self-administration behaviors of alcohol and sucrose in rats. SCH 50911 is applicable to research related to ethanol withdrawal syndrome, absence epilepsy and alcohol use disorder .
    SCH 50911
  • HY-W115752
    Hydrazine sulfate (99%)

    Diamine sulfate (99%)

    		 PEPCK Aldehyde Dehydrogenase (ALDH) Neurological Disease Metabolic Disease Cancer
    Hydrazine sulfate is an orally active PEPCK inhibitor. Hydrazine sulfate inhibits PEPCK and low-Km ALDH. Hydrazine sulfate impairs gluconeogenesis and enhances the protective effect of energy substrates against MPP + toxicity. Hydrazine sulfate exacerbates liver damage in rats when combined with Ethanol. Hydrazine sulfate can be used in the research of shock, non-small cell lung cancer, colorectal cancer and Parkinson's disease .
    Hydrazine sulfate (99%)
  • HY-N12717
    Casuarinin

    		PAK FASTK HSP p38 MAPK NF-κB NO Synthase COX HSV Caspase TNF Receptor Fungal Apoptosis Infection Inflammation/Immunology Cancer
    Casuarinin is an orally active antiproliferative, anti-inflammatory, antifungal, virucidal and gastroprotective agent. Casuarinin upregulates the expression of p21/WAF1, Fas/APO‑1, mFasL, sFasL and HSP‑70, arrests cell cycle, induces apoptosis and inhibits cancer cell proliferation. Casuarinin inhibits TNF‑α-induced phosphorylation of MAPK and activation of NF‑κB, downregulates the expression of iNOS, NF‑κB, COX‑2 and ICAM‑1, and reduces the production of proinflammatory mediators. Casuarinin attenuates ethanol-induced activation of caspase‑3 and elevation of TNF‑α, inhibits the growth of Candida albicans, and inhibits HSV‑2. Casuarinin can be used in research related to mammary adenocarcinoma, inflammatory skin diseases, gastric ulcers, candidiasis and herpes simplex virus infections .
    Casuarinin
  • HY-W097625
    6-Methoxyflavone

    		Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO) Neurological Disease Inflammation/Immunology Cancer
    6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .
    6-Methoxyflavone
  • HY-N7103R
    Ethyl oleate (Standard)

    		Reference Standards Endogenous Metabolite Others
    Ethyl oleate (Standard) is the analytical standard of Ethyl oleate. This product is intended for research and analytical applications. Ethyl oleate is an orally active fatty acid ester formed from the condensation of oleic acid and ethanol. Ethyl oleate is the main fatty acid ethyl ester in the blood after alcohol ingestion. Ethyl oleate has no obvious toxicity to rats and its absorption, distribution and excretionare similar to triacylglycerol. Ethyl oleate can accelerate the drying process of certain foods and can also be used as a liquid lipid component in nanostructured lipid carriers .
    Ethyl oleate (Standard)
  • HY-Y0943
    Isobutyramide

    		Drug Metabolite Cancer
    Aldehyde Dehydrogenase Isobutyramide is an orally active liver alcohol dehydrogenase (LADH2) inhibitor. Isobutyramide inhibits ethanol metabolism and enhances differentiation-related gene expression, inducing cell cycle arrest and significantly reducing the growth rate of prostate cancer cells (LNCaP). Isobutyramide is promising for research of advanced prostate cancer .
    Isobutyramide
  • HY-W129199
    Calcium 4-oxopentanoate

    Calcium levulinate

    		 Drug Intermediate Metabolic Disease
    Calcium 4-Oxopentanoate (levulinic acid calcium) is an effective oral calcium supplement and is commonly used as a food additive. Calcium 4-Oxopentanoate can be reduced in the liver to 4-hydroxypentanoate (HY-W107263), and ethanol enhances this reduction process. Calcium 4-Oxopentanoate can be used for studies on calcium deficiency .
    Calcium 4-oxopentanoate
  • HY-165498
    AU-461

    		Na+/K+ ATPase Metabolic Disease
    AU-461 is an orally active and reversible inhibitor of the gastric H⁺/K⁺ ATPase with IC₅₀ values for rabbit-derived and pig-derived enzymes are 12.15 μM and 4.20 μM respectively. AU-461 competes with activated cationic K⁺ (Kᵢ = 1.64 μM). AU-461 reduces both histamine-stimulated gastric acid secretion and basal gastric acid secretion in rats. AU-461 inhibits ulcer formation caused by ethanol or sodium hydroxide, and restores the plasma gastrin level to normal. AU-461 can be used for the study of peptic ulcers .
    AU-461
  • HY-114452R
    LY2940094 (Standard)

    BTRX-246040 (Standard)

    		 Opioid Receptor Reference Standards Neurological Disease
    LY2940094 (Standard) is the analytical standard of LY2940094. This product is intended for research and analytical applications. LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .
    LY2940094 (Standard)
  • HY-106083
    Quazolast

    RHC 3988

    		 Drug Intermediate Inflammation/Immunology
    Quazolast (RHC 3988) is a orally active mast cell stabilizer. Quazolast also is a potent mediator release inhibitor. Quazolast reduces the gastric damage. Quazolast has the potential for the research of gastric ulcers .
    Quazolast
  • HY-12783
    SCH 50911 hydrochloride

    		GABA Receptor Neurological Disease
    SCH 50911 dihydrochloride is a selective, orally active, blood-brain barrier permeable GABA-B receptor (GABA-B Receptor) antagonist with an IC50 of 1.1 μM in rats. SCH 50911 dihydrochloride blocks baclofen-induced antitussive effects, regulates neuronal firing and GABA release. SCH 50911 dihydrochloride promotes spontaneous seizures during withdrawal in ethanol-dependent rats, alters reward-related neurotransmission, and reduces or suppresses lever responding and self-administration behaviors of alcohol and sucrose in rats. SCH 50911 dihydrochloride is applicable to research related to ethanol withdrawal syndrome, absence epilepsy and alcohol use disorder .
    SCH 50911 hydrochloride
  • HY-165489
    AU-006

    		Endogenous Metabolite Inflammation/Immunology Endocrinology
    AU-006 is an orally active inhibitor of gastric acid secretion, with anti-ulcer effects. AU-006 does not rely on NO and mucus regulation. AU-006 significantly prevents 95% of gastric mucosal damage caused by ethanol and has broad-spectrum protective effects against chemical corrosive damage. AU-006 can be used for research on gastric ulcers .
    .
    AU-006
  • HY-124410S
    Mitoquinol-d15

    		Isotope-Labeled Compounds Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    Mitoquinol-d15 is deuterium labeled Mitoquinol (HY-124410). Mitoquinol is an orally active mitochondria-targeted antioxidant. Mitoquinol can regulate mitochondrial respiration and oxidation. Mitoquinol inhibits ROS production, and improves phagocytosis and glycolysis in ethanol-exposed macrophages via the HIF-1α-PFKP axis. Additionally, Mitoquinol can partially alleviate heat stress-induced decreases in growth performance, inflammatory responses, and metabolic disorders in pigs .
    Mitoquinol-d15
  • HY-180348
    KFP-H008

    		p38 MAPK ATP Synthase Inflammation/Immunology
    KFP-H008 is an orally active potassium-competitive acid blocker. KFP-H008 inhibits gastric acid secretion through blocking H +-K +-ATPase. KFP-H008 reduces ethanol-induced gastric ulcer index and malonaldehyde as well as proinflammatory cytokine expression in vivo. KFP-H008 downregulates p-p38 MAPK and p65 NF-κB expression. KFP-H008 blocks histamine-stimulated acid secretion in rat and dog models. KFP-H008 can be studied in research on acid-related disease, such as ethanol-induced gastric ulcer and gastric epithelial cell damage .
    KFP-H008
  • HY-182601
    MC-100093

    		EAAT Interleukin Related Neurological Disease
    MC-100093 is an orally active, blood-brain barrier-permeable GLT-1 expression upregulator . MC-100093 upregulates the expression of GLT-1 and xCT in rats, and alleviates fentanyl-induced GLT-1 downregulation, IL-6 upregulation and motor hyperactivity. MC-100093 upregulates GLT-1 expression and enhances glutamate uptake in astrocyte-neuron co-culture systems. MC-100093 reduces ethanol consumption and preference, and exerts gender-specific antidepressant-like effects . MC-100093 can be used in studies related to fentanyl overdose, mood disorders and alcohol use disorders .
    MC-100093
  • HY-W097625R
    6-Methoxyflavone (Standard)

    		Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO) Reference Standards PERK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    6-Methoxyflavone (Standard) is the analytical standard of 6-Methoxyflavone (HY-W097625). This product is intended for research and analytical applications. 6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway and activates the PERK/EIF2a/ATF4/CHOP pathway in HeLa cells. 6-Methoxyflavone acts as a Flumazenil (HY-B0009)-insensitive positive allosteric modulator at human recombinant α1β2γ2L and α2β2γ2L GABAα receptors. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .
    6-Methoxyflavone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: